arrow
H

Henrik Hjorth-Hansen

st olavs hospital hf
H指数:42
被引数:9,710

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive molecular characterization of treatment-free remission and molecular relapse in chronic myeloid leukemia patients: the EURO-SKI Biomarker Study

慢性髓性白血病患者治疗中断缓解和分子学复发的全面分子特征分析:EURO-SKI生物标志物研究

Leukemia
IF13.4
2026-06-180
OAAI
Granulocyte abundance and maturation state at diagnosis predicts treatment-free remission in CML

粒细胞数量和成熟状态在诊断时预测慢性粒细胞白血病的无治疗缓解。

Leukemia
IF13.4
2025-09-160
OAAI
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia

2025欧洲白血病网关于慢性粒细胞白血病治疗的建议

Leukemia
IF13.4
2025-07-110
OA
Computational Cytomorphological Analyses Identifies Bone Marrow Erythroblast Proportion As a Biomarker of Treatment-Free Remission in CML

计算细胞形态学分析将骨髓红细胞比例鉴定为CML治疗无复发的生物标志物

BLOOD
IF23.1
2024-11-050
PRE
Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial
LEUKEMIA
IF13.4
2024-07-102
PRE
Correction: Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial (Jan, 10.1038/s41375-024-02145-6 , 2024)

更正: 用达沙替尼再次治疗的慢性粒细胞白血病患者第二次TKI停药尝试后的无治疗缓解-DAstop2试验的中期结果 (1月,10.1038/s41375-024-02145-6,2024)

LEUKEMIA
IF13.4
2024-02-280
OAAI
Treatment-free remission after a second TKI discontinuation attempt in patients with Chronic Myeloid Leukemia re-treated with dasatinib - interim results from the DAstop2 trial

用达沙替尼再次治疗的慢性粒细胞白血病患者第二次TKI停药尝试后的无治疗缓解-DAstop2试验的中期结果

LEUKEMIA
IF13.4
2024-01-265
OAAI
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib

药物转运体OCTN1基因启动子中的SNP rs460089对伊马替尼治疗的慢性粒细胞白血病患者的无治疗缓解具有预后价值

LEUKEMIA
IF13.4
2023-12-213
OAAI
Single-cell analysis of immune recognition in chronic myeloid leukemia patients following tyrosine kinase inhibitor discontinuation

酪氨酸激酶抑制剂停用后慢性髓性白血病患者免疫识别的单细胞分析

LEUKEMIA
IF13.4
2023-11-025
OAAI
Switching from imatinib to nilotinib plus pegylated interferon-α2b in chronic phase CML failing to achieve deep molecular response: clinical and immunological effects
2023-04-294
PRE
IFN-a with dasatinib broadens the immune repertoire in patients with chronic-phase chronic myeloid leukemia
2022-09-018
OAAI
Molecular status 36 months after TKI discontinuation in CML is highly predictive for subsequent loss of MMR-final report from AFTER-SKI
LEUKEMIA
IF13.4
2021-02-1515
OAAI
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

欧洲白血病2020治疗慢性粒细胞白血病的建议

LEUKEMIA
IF13.4
2020-03-03955
OAAI
The complex genetic landscape of familial MDS and AML reveals pathogenic germline variants
2020-02-2584
OAAI
Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line

博舒替尼或伊马替尼一线治疗的新诊断CML患者的免疫学监测

2019-07-1319
OAAI